The BCR-ABL specific tyrosine kinase inhibitors (TKIs), such as imatinib (IM), are highly effective in the treatment of CML, leading to complete cytogenetic responses (CCyR) in a majority of chronic phase (CP) CML patients5. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.